- Home
- CGAU vs MESO Comparison
CGAU vs MESO Comparison
Compare CGAU & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGAU
- MESO
- Stock Information
- Founded
- CGAU 2002
- MESO 2004
- Country
- CGAU Canada
- MESO Australia
- Employees
- CGAU N/A
- MESO N/A
- Industry
- CGAU Precious Metals
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CGAU Basic Materials
- MESO Health Care
- Exchange
- CGAU Nasdaq
- MESO Nasdaq
- Market Cap
- CGAU 2.4B
- MESO 2.0B
- IPO Year
- CGAU N/A
- MESO N/A
- Fundamental
- Price
- CGAU $12.10
- MESO $14.79
- Analyst Decision
- CGAU Buy
- MESO Buy
- Analyst Count
- CGAU 3
- MESO 2
- Target Price
- CGAU $14.17
- MESO $24.00
- AVG Volume (30 Days)
- CGAU 1.6M
- MESO 175.6K
- Earning Date
- CGAU 10-28-2025
- MESO 08-28-2025
- Dividend Yield
- CGAU 1.66%
- MESO N/A
- EPS Growth
- CGAU 236.39
- MESO N/A
- EPS
- CGAU 1.60
- MESO N/A
- Revenue
- CGAU $1,285,392,000.00
- MESO $17,198,000.00
- Revenue This Year
- CGAU $9.10
- MESO $440.77
- Revenue Next Year
- CGAU $13.13
- MESO $110.74
- P/E Ratio
- CGAU $7.18
- MESO N/A
- Revenue Growth
- CGAU 2.66
- MESO 191.39
- 52 Week Low
- CGAU $5.41
- MESO $9.61
- 52 Week High
- CGAU $12.80
- MESO $22.00
- Technical
- Relative Strength Index (RSI)
- CGAU 59.21
- MESO 38.18
- Support Level
- CGAU $11.20
- MESO $14.10
- Resistance Level
- CGAU $12.56
- MESO $15.75
- Average True Range (ATR)
- CGAU 0.49
- MESO 0.45
- MACD
- CGAU 0.03
- MESO -0.15
- Stochastic Oscillator
- CGAU 77.10
- MESO 23.62
About CGAU Centerra Gold Inc.
Centerra Gold Inc a gold mining and exploration company engaged in the operation, exploration, development, and acquisition of gold properties in Asia, North America, and other markets world-wide. The company reportable operating segments are Oksut; Mount; and Milligan Molybdenum. It derives maximum revenue from Oksut segment. Geographically, it operates in Turkey, United States, Canada and Other.
About MESO Mesoblast Limited
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.